

Agenda

MOC na ASCO 2023



ESÔFAGO e ESTÔMAGO

Lucas Vieira dos Santos



MOC na ASCO 2023

- Médico Oncologista Clínico do Centro de Oncologia da BP – a Beneficência Portuguesa de São Paulo, focado em tratamento das neoplasias de cabeça e pescoço e neoplasias gastrointestinais.

- CRM 115.834 SP

Conflitos de Interesse



MOC na ASCO 2023

De acordo com a Norma 1595/2000 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro:

- Apoio educacional: Bayer, BMS, Lilly, Merck, Merck KGaA, United Medical.
- Apoio para pesquisa: BMS, Exelixis, Merck, Roche.
- Consultoria: Merck, Roche, United Medical.

Como começar?



MOC na ASCO 2023

The screenshot shows the ASCO website interface for the 2023 Annual Meeting. The main navigation includes 'Meetings & Education', 'Research & Data', 'News & Initiatives', and 'Get Involved'. The user is logged in as 'Ld'. The page displays the '2023 ASCO Annual Meeting' details, including dates (June 2-6, 2023) and location (Chicago, IL). A 'Scheduled Sessions' filter overlay is active, showing a list of session types with checkboxes and counts:

- Education Session (83)
- Oral Abstract Session (25)
- Poster Discussion Session (24)
- Poster Session (24)
- Case-Based Panel (21)
- Clinical Science Symposium (14)
- Ticketed Session (13)
- Highlights of the Day Session (3)
- Rapid Abstract Session (3)
- Award Lecture (2)

An 'Apply' button is visible at the bottom of the filter overlay. The background shows a search bar and a list of sessions for June 2, 2023, with an 'Add to Agenda' button.



Oral abstract session

- **ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.**
Presenter: Masanori Terashima, MD, PhD, FACS | Shizuoka Cancer Center, Division of Gastric Surgery
Abstract: 4000
- **Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.**
Presenter: Shuqiang Yuan, MD | State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University
Abstract: 4001



Oral abstract session

- AI blood signature in common blood tests for detection of gastric cancer in a cohort of 190,000 Individuals
Presenter: Tsz Chun Bryan Wong, MPhil | The Hong Kong University of Science and Technology
Abstract: 1500

Poster session

- Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.
Presenter: Nicole Yeung, BSc (Hons I) | Garvan Institute of Medical Research
Abstract: 3031 - Poster Bd #: 229



Poster session

- Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma.
Presenter: Shogo Takeji, MD | Department of gastroenterology and gastrointestinal oncology, National Cancer Center Hospital East
Abstract: 3041 - Poster Bd #: 239
- Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.
Presenter: Sunil Sharma | Honor Health
Abstract: 2537 - Poster Bd #: 379
- Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.
Presenter: Chenyu Mao, MD | The First Affiliated Hospital, School of Medicine, Zhejiang University
Abstract: 2576 - Poster Bd #: 418



Poster session

- A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. Presenter: Benjamin L. Schlechter, MD | DFCI/BWH cancer center
Abstract: 2519 - Poster Bd #: 361
- Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. Presenter: Yelena Y. Janjigian, MD | Memorial Sloan Kettering Cancer Center
Abstract: 4025 - Poster Bd #: 347
- Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). Presenter: Kohei Shitara, MD | Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East
Abstract: 4035 - Poster Bd #: 356



Poster session

- Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial. Presenter: Michael Masetti, MD | Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III
Abstract: 4043 - Poster Bd #: 364
- Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a single-arm, phase II clinical trial (SEEK-01). Presenter: Guangyu Yao | Zhongshan Hospital, Fudan University
Abstract: 4047 - Poster Bd #: 368
- Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response. Presenter: Eric Michael Lander, MD | Division of Hematology/Oncology, Vanderbilt University Medical Center
Abstract: 4066 - Poster Bd #: 387

Créditos

MOC na ASCO 2023 © 2023 MOC - Manual de Oncologia Clínica do Brasil. Todos os direitos reservados. São Paulo, SP.
Proibida a reprodução total ou parcial do conteúdo e imagens sem a permissão dos titulares de seus direitos autorais.

Apoio educacional:

